nuclear receptor subfamily 6 group A member 1Genealiases: CT150 · GCNF · GCNF1 · NR61 · RTR · hGCNF
Q-omics provides the consensus-scored NR6A1 profile across patient tissues and cancer cell-line models. NR6A1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NR6A1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, NR6A1 RNA expression shows 19,485 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where NR6A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR6A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR6A1 survival associations across molecular data types. NR6A1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR6A1 RNA expression–survival associations across cancer types. High NR6A1 expression shows unfavorable associations in UCEC, ACC, LIHC, KICH and UCS, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NR6A1 RNA expression.
This table summarizes NR6A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NR6A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR6A1 shows lower tumor expression in KIRC and THCA and higher tumor expression in LIHC, STAD, HNSC and COAD. The KIRC box plot shows higher NR6A1 RNA expression in normal versus tumor tissue (log2 FC = −0.532, t-test p < 0.001).
This table shows molecular features associated with NR6A1 in patient tissues and cancer cell lines. In patient samples, NR6A1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NR6A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
